Información del producto
Lifirafenib is a potent, selective and orally bioavailable, small-molecule inhibitor of the kinase activity of CDK4/6. It has potent antitumor activity in mutant melanoma xenografts that is mediated by the inhibition of epidermal growth factor receptor (EGFR) signaling. Lifirafenib also inhibits EGFR signaling in human CD4+ cells and has anti-inflammatory properties. This drug has shown to be effective against inflammatory diseases such as lupus nephritis, rheumatoid arthritis, and psoriatic arthritis. Lifirafenib is being repositioned for treatment of hematologic malignancies including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia.
Propiedades químicas
Consulta técnica sobre: 3D-WHC09079 Lifirafenib
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
